Biologics Manufacturing Innovation For Medicine Supply Security

Global patient demand for biological medicines continues to grow, driven by an increasing burden of cancers, infectious disease, and immunological and neurological disorders. The World Economic Forum reports medicine supply challenges are being faced around the world, leading to medicine shortages. Companies manufacturing biologics must have resilient supply chains that can be adapted to circumstances, such as meeting the needs of niche markets, addressing the threat of pandemics, and controlling the costs of new medicines.

FUJIFILM Diosynth Biotechnologies is fostering trusting partnerships with clients by executing its strategy of building a global network of modular-designed large-scale and single-use facilities through an aligned production platform. This will allow customers to rapidly ramp up production and transfer processes at unprecedented speed. To support clients further, we have developed an innovative single-use continuous biomanufacturing platform, providing even more agility and the potential to improve product quality while reducing medicine production costs.